NanoVation Therapeutics (UK) and NATA collaborate in a £1.6M Innovate UK Smart Grant project to create a 'one-shot' cure for cancer
HARWELL, OXFORD, UK – 1ST MARCH 2024 – NATA is pleased to announce its involvement as NanoVation Therapeutics’™ (NTx) lead partner in LIPICARE, a project aimed at revolutionising cancer treatment by combining advances in nanotechnology, gene editing and CAR-T therapy. The project is funded by a £1.6M Smart Grant from Innovate UK and includes the MRC Mary Lyon Centre and the Beatson Institute for Cancer Research as partners.
The project will focus on improving existing cancer immunotherapies that use Chimeric Antigen Receptor-T (CAR-T) cells, by genome editing of a patient’s T cells. LIPICARE will use lipid nanoparticle (LNP) technology developed by NTx to deliver messenger RNA (mRNA) to a patient’s T cells. By combining these leading-edge medical technologies, the project will ultimately lead to the development of a single-dose, personalised cancer treatment that is potent and safe, at a fraction of current treatment costs. This Smart Grant is the first step in the journey.
"We are delighted to be partners in this exciting new project”, commented Nick Lench, Executive Director at NATA. “The combination of cutting-edge technologies promises to deliver new approaches to personalised cancer therapy.”
“We believe that LIPICARE’s approach to cancer therapy will be of enormous value to patients, offering a safe and effective treatment at reduced cost, and requiring only a single dose.”
said project lead and NTx Managing Director, Arpan Desai.
Click here for more information on NanoVation Therapeutics.